icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
cVLdfC3UMCt7Je3q
Listen
